

GILOTRIF - (20,30,40 mg; Tablet, Oral)

| | | | |
|------------------------------|---|-----------------------------|----------------------|
| Generic Name | AFATINIB DIMALEATE | Innovator | Boehringer Ingelheim |
| Dosage | 20,30,40 mg; Tablet, Oral | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | More Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | None | Generic Launches | None |
| Indication | Used to treat people with non-small cell lung cancer (NSCLC) that: has certain (non-resistant) abnormal epidermal growth factor receptor (EGFR) geneY | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.